Evaluation of the Combination of Docetaxel/Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study

REFERENCES

• Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin. Oncol. 1988; 15: 70–85
   PubMed Web of Science ®Google Scholar
• Schantz S. P., Harrison L. B., Forastiere A. A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx. Cancer: Principles and Practice of Oncology, V. T. De Vita, S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 741–803
   Google Scholar
• Kish J. A., Weaver A., Jacobs J., Cummings G., Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819–1824
   PubMed Web of Science ®Google Scholar
• Forastiere A. A., Metch B., Schuller D. E., Ensley J. F., Hutchins L. F., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J. Clin. Oncol. 1992; 10: 1245–1251
   PubMed Web of Science ®Google Scholar
• Jacobs C., Lyman G., Velez Garcia E., Sridhar K. S., Knight W., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992; 10: 257–263
   PubMed Web of Science ®Google Scholar
• Bruno R., Sanderink G. J. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surveys 1993; 17: 305–313
   PubMedGoogle Scholar
• Ringel I., Horwitz S. B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 1991; 83: 288–291
   PubMed Web of Science ®Google Scholar
• Extra J. M., Rousseau F., Bruno R., Clavel M., Le Bail N., Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993; 53: 1037–1042
   PubMed Web of Science ®Google Scholar
• Bissery M. C., Guenard D., Gueritte-Voegelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991; 51: 4845–4852
   PubMed Web of Science ®Google Scholar
• Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. 1994; 5: 495–505
   PubMed Web of Science ®Google Scholar
• Burris H., Irvin R., Kuhn J., Kalter S., Smith L., et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol. 1993; 11: 950–958
   PubMed Web of Science ®Google Scholar
• Braakhuis B. J., Kegel A., Welters M. J. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett. 1994; 81: 151–154
   PubMed Web of Science ®Google Scholar
• Dreyfuss A. I., Clark J. R., Norris C. M., Rossi R. M., Lucarini J. W., et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1996; 14: 1672–1678
   PubMed Web of Science ®Google Scholar
• Catimel G., Verweij J., Mattijssen V., Hanauske A., Piccart M., et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group. Ann. Oncol. 1994; 5: 533–537
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M., Metch B., Kish J., Ensley J., Rinehart J. J., Schuller D. E., Coltman C. A. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat. Rep. 1987; 71: 723–726
   PubMedGoogle Scholar
• Calvert H., Judson I., van der Vijgh W. J. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv. 1993; 17: 189–217
   PubMedGoogle Scholar
• Green S., Weiss G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 1992; 10: 239–253
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Belani C. P., Aisner J., Hiponia D., Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 1995; 22: 7–12
   PubMed Web of Science ®Google Scholar
• Jahanzeb M., Sarna G., Hirsch R., Radice P., Koletsky A., et al. Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res. 2004; 24: 1239–1242
   PubMed Web of Science ®Google Scholar
• Ramalingam S., Dobbs T. W., Einzig A. I., Wojtowicz-Praga S., Cascino M., Bonomi P., Belani C. P. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study. Cancer Chemother. Pharmacol. 2004; 53: 439–444
   PubMed Web of Science ®Google Scholar
• Fossella F., Pereira J. R., von Pawel J., Pluzanska A., Gorbounova V., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003; 21: 3016–3024
   PubMed Web of Science ®Google Scholar
• Pfisterer J., du Bois A., Wagner U., Quaas J., Blohmer J. U., Wallwiener D., Hilpert F. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. a phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol. Oncol. 2004; 92: 949–956
   Google Scholar
• Vorobiof D. A., Rapoport B. L., Chasen M. R., Cohen G. L., Mahomed R., Karime M. Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Int. J. Gynecol. Cancer 2003; 13: 287–291
   PubMed Web of Science ®Google Scholar
• Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol. 2001; 19: 1901–1905
   PubMed Web of Science ®Google Scholar
• Rein D. T., Kurbacher C. M., Breidenbach M., Schondorf T., Schmidt T., et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol. Oncol. 2002; 87: 98–103
   PubMed Web of Science ®Google Scholar
• von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin. Oncol. 2002; 29: 3–14
   Google Scholar
• Mavroudis D., Alexopoulos A., Malamos N., Ardavanis A., Kandylis C., et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin a multicenter phase II trial. Oncology 2003; 64: 207–212
   PubMed Web of Science ®Google Scholar
• Glisson B. S., Murphy B. A., Frenette G., Khuri F. R., Forastiere A. A., Phase I I. Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2002; 20: 1593–1599
   PubMed Web of Science ®Google Scholar
• Gedlicka C., Formanek M., Selzer E., Burian M., Kornfehl J., et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 2002; 63: 145–150
   PubMed Web of Science ®Google Scholar
• Baur M., Kienzer H. R., Schweiger J., DeSantis M., Gerber E., et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. Cancer 2002; 94: 2953–2958
   PubMed Web of Science ®Google Scholar
• Specht L., Larsen S. K., Hansen H. S. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann. Oncol. 2000; 11: 845–849
   PubMed Web of Science ®Google Scholar
• Fossella F. V., Lee J. S., Shin D. M., Calayag M., Huber M., et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 645–651
   PubMed Web of Science ®Google Scholar